围手术期白蛋白缺乏替代治疗(SuperAdd)在血管、腹部、创伤或骨科手术成人患者中的随机对照试验方案
SuperAdd 是一项单中心、前瞻性、随机、结局评估者盲、患者盲的对照试验,旨在探讨以维持血清白蛋白浓度>30 g/l 为目标的人血白蛋白替代治疗能否减少血容量正常手术患者的术后并发症。研究纳入 ASA III 或 IV 级或接受高风险手术的成人患者,在白蛋白浓度低于 30 g/l 时随机分入对照组或治疗组,主要结局为根据 Clavien-Dindo 评分≥2 分的术后并发症发生率。
要点
- 目标导向白蛋白替代旨在维持血清白蛋白>30 g/l。
- 主要结局为 Clavien-Dindo 评分≥2 分的术后并发症频率。
- 纳入 ASA III/IV 级或高风险手术的成人患者。
核心结论
- SuperAdd 是首个在手术人群中研究以血清白蛋白>30 g/l 为目标的目标导向白蛋白替代效果的临床试验。
研究设计与样本
- 单中心、前瞻性、随机、结局评估者盲、患者盲的对照试验。
- 纳入 ASA III 或 IV 级或接受高风险手术的成人患者,签署知情同意后招募。
- 麻醉诱导前及每 3 小时监测白蛋白浓度直至进入麻醉后监护室,低于 30 g/l 时随机分组。
关键数值与推荐
- 研究干预为目标导向人血白蛋白替代,旨在手术期间及麻醉后监护室停留期间维持白蛋白浓度>30 g/l。
- 对照组按标准临床护理治疗。
- 主要结局为采用术后发病率调查评估的 Clavien-Dindo 评分≥2 分的术后并发症频率。
- 术后第 1、3、5、8、15 天进行随访,术后 6 个月电话随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypalbuminemia is associated with numerous postoperative complications, so a perioperative albumin substitution is often considered. The objective of SuperAdd is to investigate whether substitution of human albumin, aiming to maintain a serum concentration > 30 g/l, can reduce postoperative complications in normovolemic surgical patients in comparison with standard care. METHODS/DESIGN: SuperAdd is a single-center, prospective, randomized, outcome-assessor blinded, patient blinded controlled trial. The primary outcome is the frequency of postoperative complications identified using the Postoperative Morbidity Survey graded ≥ 2 according to the Clavien-Dindo Score. Adult patients at risk to develop hypalbuminemia, i.e., ASA III or IV or high-risk surgery, are recruited after written informed consent was obtained. The albumin concentration is assessed before the induction of anesthesia and every 3 h until admission to the postanesthesia care unit. If albumin concentrations drop below 30 g/l, patients are randomly allocated to the control or the treatment group. The study intervention is a goal-directed human albumin substitution aimed at a concentration > 30 g/l during surgery and postanesthesia care unit stay. The patients in the control group are treated according to standard clinical care. Postoperative visits are to be performed on days 1, 3, 5, 8, and 15, as well as by telephone 6 months after surgery. DISCUSSION: SuperAdd is the first clinical trial in a surgical population investigating the effect of a goal-directed albumin substitution aiming at a serum level > 30 g/l. The nonrestrictive selection of patients guarantees that the patients without albumin screening will most likely not develop hypalbuminemia, thus ensuring generalizability of the study results. TRIAL REGISTRATION: EudraCT 2016-001313-24. Registered on 5 September 2016. Clinical Trials NCT03167645. Registered on 18 October 2016 and has the Universal Trial Number (UTN) U1111-1181-2625.
引用
- Schaller SJ, Fuest K, Ulm B, et al. Substitution of perioperative albumin deficiency disorders (SuperAdd) in adults undergoing vascular, abdominal, trauma, or orthopedic surgery: protocol for a randomized controlled trial. Trials. 2020. PMID: 32811539. doi:10.1186/s13063-020-04626-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。